BioXcel Therapeutics
BTAI
BTAI
74 hedge funds and large institutions have $12.5M invested in BioXcel Therapeutics in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
74
Holders Change
+1
Holders Change %
+1.37%
% of All Funds
1.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
21
Reduced
20
Closed
21
Calls
$159K
Puts
$346K
Net Calls
-$187K
Net Calls Change
+$145K
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$3.35M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$322K |
| 3 |
Jane Street
New York
|
+$160K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$106K |
| 5 |
Millennium Management
New York
|
+$99.4K |
Top Sellers
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.63M |
| 2 |
BlackRock
New York
|
-$1.14M |
| 3 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$851K |
| 4 |
State Street
Boston,
Massachusetts
|
-$435K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$370K |
